Structure Therapeutics Net Tangible Assets Over Time
| GPCR Stock | 33.75 0.01 0.03% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Structure Therapeutics Performance and Structure Therapeutics Correlation. Structure |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Structure Therapeutics. If investors know Structure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Structure Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.16) | Return On Assets (0.13) | Return On Equity (0.18) |
The market value of Structure Therapeutics is measured differently than its book value, which is the value of Structure that is recorded on the company's balance sheet. Investors also form their own opinion of Structure Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Structure Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Structure Therapeutics' market value can be influenced by many factors that don't directly affect Structure Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Structure Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Structure Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Structure Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Tangible Assets Analysis
Compare Structure Therapeutics and related stocks such as Day One Biopharmaceu, X4 Pharmaceuticals, and Inozyme Pharma Net Tangible Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAWN | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (54.2 M) | 281.1 M | 332 M | 381.8 M | 400.9 M |
| XFOR | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (44.5 M) | (77.1 M) | 102.1 M | 45.7 M | 47.1 M | 56.7 M | 65.2 M | 68.5 M |
| INZY | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (33.2 M) | 158.1 M | 109.3 M | 118.4 M | 136.2 M | 74.5 M |
| ABOS | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (18.6 M) | 225.2 M | 188.8 M | 217.1 M | 227.9 M |
| MREO | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 53.4 M | 29.5 M | 139 K | (4.2 M) | (46.6 M) | 63.4 M | 37.8 M | 43.4 M | 45.6 M |
| TERN | (22.7 M) | (22.7 M) | (22.7 M) | (22.7 M) | (22.7 M) | (22.7 M) | (22.7 M) | (22.7 M) | (22.7 M) | (90.8 M) | (117.4 M) | 172.2 M | 276.9 M | 318.5 M | 334.4 M |
| ELDN | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | 17.6 M | 12.6 M | 9.5 M | 109.6 M | 83 M | 83 M | 95.4 M | 100.2 M |
| HOOK | (42.7 M) | (42.7 M) | (42.7 M) | (42.7 M) | (42.7 M) | (42.7 M) | (42.7 M) | (42.7 M) | (60.4 M) | 117.9 M | 156.1 M | 89.6 M | 102.5 M | 117.9 M | 66.6 M |
| BMEA | (21 K) | (21 K) | (21 K) | (21 K) | (21 K) | (21 K) | (21 K) | (21 K) | (21 K) | (21 K) | 5.2 M | 178.8 M | 108.5 M | 124.8 M | 80.4 M |
| IRON | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (28.8 M) | (64.2 M) | (64.2 M) | (57.8 M) | (60.7 M) |
Structure Therapeutics and related stocks such as Day One Biopharmaceu, X4 Pharmaceuticals, and Inozyme Pharma Net Tangible Assets description
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.My Equities
My Current Equities and Potential Positions
| Structure Therapeutics American | GPCR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
null 33.75
Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.